212 related articles for article (PubMed ID: 29857824)
1. Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer.
Dias LP; Luzo ÂCM; Volpe BB; Durán M; Galdames SEM; Ferreira LAB; Durán N; Fávaro WJ
Tissue Cell; 2018 Jun; 52():17-27. PubMed ID: 29857824
[TBL] [Abstract][Full Text] [Related]
2. Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.
Garcia PV; Apolinário LM; Böckelmann PK; da Silva Nunes I; Duran N; Fávaro WJ
Int J Clin Exp Pathol; 2015; 8(5):4427-43. PubMed ID: 26191134
[TBL] [Abstract][Full Text] [Related]
3. Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model.
Fávaro WJ; Socca EAR; Böckelmann PK; Reis IB; Garcia PV; Durán N
Med Oncol; 2022 Jan; 39(2):24. PubMed ID: 34982270
[TBL] [Abstract][Full Text] [Related]
4. A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad® immunotherapy associated with platelet-rich plasma.
Ribeiro de Souza B; Brum Reis I; Cardoso de Arruda Camargo G; Oliveira G; Cristina Dias Q; Durán N; José Fávaro W
Int Immunopharmacol; 2023 Oct; 123():110723. PubMed ID: 37531827
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer.
Reis LO; Ferreira U; Billis A; Cagnon VH; Fávaro WJ
J Urol; 2012 Feb; 187(2):438-45. PubMed ID: 22177150
[TBL] [Abstract][Full Text] [Related]
6. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
[TBL] [Abstract][Full Text] [Related]
7. Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.
Passos GR; Camargo JA; Ferrari KL; Saad MJA; de Mattos AC; Reis LO
Med Oncol; 2017 Dec; 35(1):3. PubMed ID: 29209984
[TBL] [Abstract][Full Text] [Related]
8. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
9. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
10. Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
Garcia PV; Seiva FR; Carniato AP; de Mello Júnior W; Duran N; Macedo AM; de Oliveira AG; Romih R; Nunes Ida S; Nunes Oda S; Fávaro WJ
BMC Cancer; 2016 Jul; 16():422. PubMed ID: 27389279
[TBL] [Abstract][Full Text] [Related]
11. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
13. Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer.
Ayari C; Besançon M; Bergeron A; LaRue H; Bussières V; Fradet Y
Cancer Immunol Immunother; 2016 Feb; 65(2):223-34. PubMed ID: 26759009
[TBL] [Abstract][Full Text] [Related]
14. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
16. Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guérin Downregulation of Nonmuscle-invasive Bladder Cancer.
Camargo JA; Passos GR; Ferrari KL; Billis A; Saad MJA; Reis LO
Clin Genitourin Cancer; 2018 Jun; 16(3):e587-e593. PubMed ID: 29174504
[TBL] [Abstract][Full Text] [Related]
17. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model.
Steinberg GD; Brendler CB; Squire RA; Isaacs JT
J Urol; 1991 Mar; 145(3):647-53. PubMed ID: 1997724
[TBL] [Abstract][Full Text] [Related]
18. Intravesical BCG Induces CD4
Kates M; Nirschl T; Sopko NA; Matsui H; Kochel CM; Reis LO; Netto GJ; Hoque MO; Hahn NM; McConkey DJ; Baras AS; Drake CG; Bivalacqua TJ
Cancer Immunol Res; 2017 Jul; 5(7):594-603. PubMed ID: 28588015
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
[TBL] [Abstract][Full Text] [Related]
20. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
